Trial · NCT06468436
Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients
NCT06468436, Not applicable, Not yet recruiting, Peking University First Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients. Trials, record NCT06468436. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06468436
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients
- NCT number
- NCT06468436
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 1,508 participants, estimated
- Lead sponsor
- Peking University First Hospital
- Conditions
- Aged, Intensive Care Units, Ventilators, Mechanical, Dexmedetomidine, Esketamine, Delirium
- Interventions
- Dexmedetomidine-Esketamine Combination, Dexmedetomidine
- First posted
- 2024-06-21
- Last updated
- 2025-07-31
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of delirium within 7 days | Up to 7 days after enrollment | Delirium is assessed twice daily with the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) or the 3-Minute Diagnostic Assessment for Delirium using the Confusion Assessment Method (3D-CAM) during the 7-day period after enrollment or until hospital discharge. Positive result of delirium assessments at any timepoint is defined as occurrence of delirium. |
| Secondary | Days alive without delirium or come during the 7-day period | Up to 7 days after enrollment | Delirium is assessed twice daily with the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) or the 3-Minute Diagnostic Assessment for Delirium using the Confusion Assessment Method (3D-CAM). Coma is defined as Richmond Agitation Sedation Scale (score ranges from -5 \[unarousable\] to +4 \[combative\] and 0 indicates alert and calms) of -4 or -5. Positive results at any timepoint is defined as occurrence of delirium or coma. |
| Secondary | Ventilator-free days within 30 days | Up to 30 days after enrollment | Mechanical ventilation includes both invasive and non-invasive ventilation, but do not include high-flow nasal oxygenation. |
| Secondary | Length of stay in the ICU | Up to 30 days after enrollment | Length of stay in the ICU. |
| Secondary | 30-day all-cause mortality | Up to 30 days after enrollment | 30-day all-cause mortality. |
| Other | Proportion of patients without delirium | Up to 7 days after enrollment | Delirium is assessed twice daily with the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) or the 3-Minute Diagnostic Assessment for Delirium using the Confusion Assessment Method (3D-CAM) during the 7-day period after enrollment or until hospital discharge. |
| Other | Proportion of patients without delirium or coma | Up to 7 days after enrollment | Delirium is assessed twice daily with the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) or the 3-Minute Diagnostic Assessment for Delirium using the Confusion Assessment Method (3D-CAM). Coma is defined as Richmond Agitation Sedation Scale (score ranges from -5 \[unarousable\] to +4 \[combative\] and 0 indicates alert and calms) of -4 or -5. |
| Other | Length of stay in hospital after enrollment | Up to 30 days after enrollment | Length of stay in hospital after enrollment. |
| Other | Incidence of major complications within 30 days | Up to 30 days after enrollment | Major complications are defined as new-onset medical conditions other than delirium that are deemed harmful and require therapeutic intervention, that is grade II or higher on the Clavien-Dindo classification. |
| Other | Incidence of cognitive dysfunction at 30 days | At 30 days after enrollment | Cognitive function is assessed with the Montreal Cognitive Assessment-telephone version (T-MoCA; score ranges from 0 to 22, with higher score indicating better cognitive function). A decline of 1 standard deviation (SD) or more from baseline is defined as having cognitive dysfunction. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers70
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06468436
GET https://conductscience.org/api/trials/v1/NCT06468436/papers?page=2